UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 599

Sortiert nach

1,5‐Diphenylpent‐4‐ene‐1,3‐dione

Acta crystallographica. Section E, Structure reports online, 2002-11, Vol.58 (11), p.o1301-o1303

2002

Link zum Volltext

Verfügbarkeit prüfen

1,5-Diphenylpent-4-ene-1,3-dione

Acta crystallographica. Section E, Structure reports online, 2002-11, Vol.58 (11), p.o1301-o1303

2002

Link zum Volltext

Verfügbarkeit prüfen

12: The Safety and antibody kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients

Journal of the Pediatric Infectious Diseases Society, 2021-06, Vol.10 (Supplement_2), p.S7-S7

2021

Link zum Volltext

Verfügbarkeit prüfen

1342. Serial Microbial Cell-Free DNA Next Generation Sequencing (NGS) As A Means of Diagnosis and Monitoring of Clinical Response To Treatment Of Invasive Fungal Infections (IFI) In Immunocompromised Pediatric Patients

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Link zum Volltext

Verfügbarkeit prüfen

1418. Pharmacokinetics (PK) and Toxicity of Intravenous Amikacin (AMK) Dosed Three Times a Week (TIW) for Treatment of Disseminated Mycobacterium abscessus Infection in Children

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S437-S437

2018

Link zum Volltext

Verfügbarkeit prüfen

1432. County-Wide Pediatric IPD Experience Following Prevnar 13 Implementation

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S442-S443

2018

Link zum Volltext

Verfügbarkeit prüfen

1675. Community Acquired Serious Bacterial Infections in Pediatric Patients Before and After COVID: Could Masks Save Lives?

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

1676. PK, Safety and Tolerability of VABOMERE® (meropenem-vaborbactam) in Infants, Children and Adolescents

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S52-S52

2018

Link zum Volltext

Verfügbarkeit prüfen

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy

Clinical infectious diseases, 2019-01, Vol.68 (1), p.1-4

2019

Link zum Volltext

Verfügbarkeit prüfen

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy

Clinical infectious diseases, 2019-01, Vol.68 (1), p.e1-e35

2019

Link zum Volltext

Verfügbarkeit prüfen

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya

Clinical infectious diseases, 2019-01, Vol.68 (1), p.e1-e35

2019

Link zum Volltext

Verfügbarkeit prüfen

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya

Clinical infectious diseases, 2019-01, Vol.68 (1), p.1-4

2019

Link zum Volltext

Verfügbarkeit prüfen

241A Pilot Study Evaluating Urine to Plasma Ratios of Inflammatory Cytokines to Allow for Discrimination of Urinary Tract as the Source of Serious Bacterial Infections in Young Febrile Infants

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S107-S107

2015

Link zum Volltext

Verfügbarkeit prüfen

2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

2462-PUB: Differences between Type 1 Diabetes Adults With and Without Lipid-Lowering Treatment

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

2578. Trends in Pathogens and Antibiotic Treatment in Children with Cystic Fibrosis in 2018 and 2022: A Retrospective Multicenter Study

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

342. Clinical Utility of a Next Generation Sequencing Test for Pathogen Detection in Pediatric Central Nervous System Infections

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S241-S241

2020

Link zum Volltext

Verfügbarkeit prüfen

5-(1 H -Indol-3-yl)-1-phenylpent-4-ene-1,3-dione

Acta crystallographica. Section E, Structure reports online, 2003-04, Vol.59 (4), p.o524-o526

2003

Link zum Volltext

Verfügbarkeit prüfen

5‐(1H‐Indol‐3‐yl)‐1‐phenylpent‐4‐ene‐1,3‐dione

Acta crystallographica. Section E, Structure reports online, 2003-04, Vol.59 (4), p.o524-o526

2003

Link zum Volltext

Verfügbarkeit prüfen

5‐(2‐Furyl)‐3‐hydroxy‐1‐phenylpenta‐2,4‐dien‐1‐one

Acta crystallographica. Section E, Structure reports online, 2004-12, Vol.60 (12), p.o2444-o2446

2004

Link zum Volltext

Verfügbarkeit prüfen

5-(2-Furyl)-3-hydroxy-1-phenylpenta-2,4-dien-1-one

Acta crystallographica. Section E, Structure reports online, 2004-12, Vol.60 (12), p.o2444-o2446

2004

Link zum Volltext

Verfügbarkeit prüfen

5‐(4‐Hydroxy‐3‐methoxyphenyl)‐1‐phenylpent‐4‐ene‐1,3‐dione

Acta crystallographica. Section E, Structure reports online, 2004-05, Vol.60 (5), p.o919-o921

2004

Link zum Volltext

Verfügbarkeit prüfen

5-(4-Hydroxy-3-methoxyphenyl)-1-phenylpent-4-ene-1,3-dione

Acta crystallographica. Section E, Structure reports online, 2004-05, Vol.60 (5), p.o919-o921

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 599

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(499)
Mit Volltextzugriff
(539)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

1,5‐Diphenylpent‐4‐ene‐1,3‐dione

1,5-Diphenylpent-4-ene-1,3-dione

12: The Safety and antibody kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients

1342. Serial Microbial Cell-Free DNA Next Generation Sequencing (NGS) As A Means of Diagnosis and Monitoring of Clinical Response To Treatment Of Invasive Fungal Infections (IFI) In Immunocompromised Pediatric Patients

1418. Pharmacokinetics (PK) and Toxicity of Intravenous Amikacin (AMK) Dosed Three Times a Week (TIW) for Treatment of Disseminated Mycobacterium abscessus Infection in Children

1432. County-Wide Pediatric IPD Experience Following Prevnar 13 Implementation

1675. Community Acquired Serious Bacterial Infections in Pediatric Patients Before and After COVID: Could Masks Save Lives?

1676. PK, Safety and Tolerability of VABOMERE® (meropenem-vaborbactam) in Infants, Children and Adolescents

1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya

241A Pilot Study Evaluating Urine to Plasma Ratios of Inflammatory Cytokines to Allow for Discrimination of Urinary Tract as the Source of Serious Bacterial Infections in Young Febrile Infants

2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience

2462-PUB: Differences between Type 1 Diabetes Adults With and Without Lipid-Lowering Treatment

2578. Trends in Pathogens and Antibiotic Treatment in Children with Cystic Fibrosis in 2018 and 2022: A Retrospective Multicenter Study

342. Clinical Utility of a Next Generation Sequencing Test for Pathogen Detection in Pediatric Central Nervous System Infections

5-(1 H -Indol-3-yl)-1-phenylpent-4-ene-1,3-dione

5‐(1H‐Indol‐3‐yl)‐1‐phenylpent‐4‐ene‐1,3‐dione

5‐(2‐Furyl)‐3‐hydroxy‐1‐phenylpenta‐2,4‐dien‐1‐one

5-(2-Furyl)-3-hydroxy-1-phenylpenta-2,4-dien-1-one

5‐(4‐Hydroxy‐3‐methoxyphenyl)‐1‐phenylpent‐4‐ene‐1,3‐dione

5-(4-Hydroxy-3-methoxyphenyl)-1-phenylpent-4-ene-1,3-dione

Suchergebnisse filtern